Operating cash flow swung from $2.6B in 2026Q1 to negative $1.2B in 2026Q3, with $1.6B of investment sales partly bridging the outflow, suggesting cash conversion remains unstable.
Oscar Health, Inc. (OSCR) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | 4.14B | 1.09B | 978.19M | -272.16M | 380.35M | -181.75M | 222.73M | -165.37M |
| Operating CF Growth % | 569.55% | 11.93% | 459.42% | -171.56% | 309.28% | -181.6% | 234.69% | - |
| Operating CF / Revenue % | 23.68% | 9.36% | 10.66% | -4.64% | 9.22% | -9.46% | 37.77% | -29.86% |
| Net Income | 855.5M | -442.9M | 26.12M | -270.59M | -609.55M | -571.43M | -406.82M | -261.18M |
| Depreciation & Amortization | 27.47M | 28.89M | 32.15M | 30.69M | 15.28M | 14.61M | 11.29M | 6.9M |
| Stock-Based Compensation | 77M | 87.65M | 109.82M | 159.68M | 112.33M | 86.3M | 35.87M | 33.56M |
| Deferred Taxes | -1.69M | 2.45M | -2.34M | 58K | -165K | -101K | -67K | -426K |
| Other Non-Cash Items | 3.59B | -40.24M | -26.42M | 86K | 7.46M | 41.19M | 6.77M | -6.43M |
| Working Capital Changes | -413.95M | 1.46B | 838.86M | -192.09M | 855M | 247.7M | 575.7M | 62.21M |
| Cash from Investing | -1.89B | -241.06M | -1.39B | 577.19M | -226.52M | -774.51M | -344.71M | 150.51M |
| Capital Expenditures | -40.93M | -36.37M | -27.9M | -25.58M | -29.01M | -25.89M | -14.02M | -26M |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 7.23M | 0 | 0 |
| Purchase of Investments | -5.18B | -1.01B | -2.13B | -836.98M | -1.19B | -1.81B | -1B | -877.67M |
| Sale/Maturity of Investments | 3.32B | 804.96M | 770.04M | 1.44B | 994.08M | 1.05B | 671.59M | 1.06B |
| Other Investing | 1.26M | 4.28M | 3.93M | -2.28M | 1.12M | -555K | -1.24M | -7.08M |
| Cash from Financing | 27.58M | 399.21M | 68.39M | 6.45M | 301.11M | 1.24B | 611.71M | -2.12M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.99M |
| Stock Issued | 24.77M | 55.03M | 68.39M | 3.96M | 1.3M | 1.35B | 0 | 0 |
| Debt Issuance (Net) | -1000K | 1000K | 0 | 0 | 1000K | -1000K | 1000K | 0 |
| Other Financing | 7.49M | -4.04M | 0 | 2.49M | -5.19M | 43.56M | 89.04M | 873K |
| Net Change in Cash | 2.26B | 1.25B | -340.85M | 311.47M | 454.94M | 282.45M | 489.73M | -16.98M |
| Exchange Rate Effect | -6.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 4.1B | 1.55B | 1.89B | 1.58B | 1.13B | 843.11M | 353.38M | 370.36M |
| Cash at End | 4.49B | 2.8B | 1.55B | 1.89B | 1.58B | 1.13B | 843.11M | 353.38M |
| Free Cash Flow | 4.1B | 1.06B | 950.3M | -297.74M | 351.34M | -207.63M | 208.71M | -191.37M |
| FCF Growth % | 456.88% | 11.38% | 419.17% | -184.74% | 269.21% | -199.48% | 209.06% | - |
| FCF Margin % | 23.45% | 9.05% | 10.35% | -5.08% | 8.52% | -10.81% | 35.4% | -34.56% |
| FCF per Share | 11.82 | 4.03 | 3.57 | -1.34 | 1.65 | -1.16 | 0.87 | -0.8 |
Quick answers to the most common questions about buying OSCR stock.
Oscar Health, Inc. (OSCR) generated $1.09B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Oscar Health, Inc. (OSCR) generated $1.06B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Oscar Health, Inc. (OSCR) spent $36.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Volatile underwriting cash conversion
Metrics are mathematically derived from official filings.
Float Swings Mask Underlying Cash Generation
Based on reported quarterly figures, Oscar's operating cash flow swung from $2.6B in 2026Q1 to negative $1.2B in 2026Q3, a range too wide to read as a stable premium-to-claims float pattern.
The oscillation suggests that timing of premium receipts relative to claims payments, along with risk adjustment settlements, is driving much of the cash variability rather than steady underwriting economics. Operating cash flow to net income ratios ranging from -7.18 to 9.16 further indicate that net income is a weak guide to cash generation in this period. Investors should monitor whether claims paid of $4.2B in 2026Q3 reflect seasonal utilization or a durable shift in medical cost trends.
Portfolio Liquidations Funding Operating Outflows
According to reported cash flow data, Oscar sold $1.6B of investments in 2026Q3 while purchasing none, suggesting the quarter's negative operating cash flow was partly bridged by portfolio liquidation.
Heavy net sales of investments in the most recent quarter, following substantial net purchases of $4.0B in 2026Q2, point to an active reallocation of the float rather than a passive holding pattern. This raises the question of whether the investment portfolio is being used as a liquidity buffer for claims timing. The pattern warrants further investigation into the duration profile of the remaining holdings.
Earnings Inflection Not Yet Cash-Confirmed
Based on EDBL-style reporting, Oscar's net income of $679.0M in 2026Q1 was accompanied by $2.6B in operating cash flow, but 2026Q3 net income of $167.3M coincided with negative operating cash flow of $1.2B.
The divergence between reported profit and operating cash in the latest quarter may indicate that accrual-based items such as reserve movements and risk adjustment receivables are absorbing cash. Profitability has not yet been consistently reflected in cash generation across the ten-quarter window. The stated earnings beat should therefore be weighed against cash conversion before drawing conclusions about sustainability.
Claims Outflows Rising Faster Than Premium Inflows
As reported in financial statements, Oscar's claims and loss payments climbed from $2.1B in 2024Q4 to $4.2B in 2026Q3, a rise that warrants comparison against premium growth to assess medical cost pressure.
Claims outflows roughly doubling over the period is consistent with the reported 72.1% year-over-year revenue growth, but without a matched premium series it is difficult to confirm whether the medical loss ratio is improving. Rising paid claims during membership expansion may indicate higher early-enrollee utilization or inflation in provider rates. Investors should monitor whether claim payment lags are lengthening, as this would affect the float available to fund operations.
Cash Data Gaps Limit Conclusions
Several quarters report zero dividends, buybacks, and some investment activity, and premium collection data is not separately disclosed, so parts of the cash picture remain data unavailable.
Where fields are blank or zero, this analysis treats them as data unavailable rather than inferring a cause. The absence of premium receivable and broker lag data prevents direct testing of premium conversion efficiency. Conclusions about float generation should therefore be treated as provisional until fuller cash flow disclosure is reviewed.